BioLargo, Inc. · OTC:BLGO
BioLargo — Shareholder Meeting (June 2022)
29 slides from BioLargo's shareholder meeting presentation, Jun 2, 2022
Slide 1: 2022 Annual Stockholder's Meeting
S BioLargo Ss We Make Life Better m 2022 Annual stockholder's Meeting OTCQB: BLGO ~— Westminster, CA ‘Safe Harbor Statement ancl lass. There can be. epee june bebe
Slide 2: We Make Life Better
by BioLargo We Make Life Better (Gy BioLargo OBioLarge Water / +) Aen [CXR
Slide 3: Looking back
Looking back v Record revenue ¥ One profitable business unit (Q1) and another near to profitability v New partnerships ¥ Breakthrough technologies ready for market ¥ Debt drastically reduced Y Net loss improved; liabilities reduced v Expenses from interest and debt extinguishment reduced to inconseq
Slide 4: Financial highlights
$1200k $1000k $800k $600k. $400k $200k $0 {21.22.03 a4/a1 a2 03 24/01 22 03.08/01 02.03 a¢|a1 02.03 asa}! 2017 Financial highlights Quarterly Revenue Debt* 2018 2019 2020 2021 2022 2017 2018 2019 —AllBiolargo ir faut k ing, and $50K ir 2020 mBioLargo = Clyra 2021 March 1, 2023 (does not include debt
Slide 5: Strategy for accelerated growth and achieving positive cash flow from operations
Strategy for accelerated growth and achieving positive cash flow from operations Leaning into channel partnerships Launch of New Technologies
Slide 6: Key catalysts for growth
Key catalysts for growth O Garratt CALLAHAN WASTEWATER EQUIPMENT PARTNERSHIP ala @POOPH® IKIGAI HOLDINGS 74» PET ODOR CONTROL REAS TREATMENT
Slide 7: Waste to Energy Project - South America
BioLargo Engineering, Scence & Technologies Waste to Energy Project - South America * Multistage - Multidiscipline project + Currently in Stage 1 - Feasibility Study for an 8,000 ton per day Waste to Energy facility + Stage 2 - Summer 2022 - Design Basis - $750K plus + Stage 3 - Process Design (Fron
Slide 8: Engineering, Science & Technologies
Engineering, Science & Technologies sie _'QpBioLargo
Slide 9: Garratt - Callahan MLD Product Line
Garratt - Callahan MLD Product Line + Proven commercially viable at our water lab in Oak Ridge + Technology scaled up and commercially sound + Systems to be designed, fabricated, and integrated by BioLargo + Unique patented product only available through G-C & BioLargo * G-C expects to sell 30 to 50
Slide 10: Ultra Safe Nuclear Corporation
Ultra Safe Nuclear Corporation * Small, intrinsically safe nuclear reactors + Remote locations (e.g., space) * BioLargo engineers: designing, integrating, and fabricating nuclear fuel production systems * Discussing second and third generation systems
Slide 11: Aqueous Electrostatic Concentrator
Cc CARBON FILTRATION/ = MEDIA FILTRATION a AQUEOUS ELECTROSTATIC CONCENTRATOR ( BioLargo
Slide 12: PFAS - AEC Exceptional Performance
PFAS - AEC Exceptional Performance * Removes PFAS (Non-Detect) + Results across a broad range of PFAS chemicals + Test results open doors for partners and customers
Slide 13: Target Markets and Business Model
Target Markets and Business Model + More than 2900 sites — including public water systems, military bases, and industrial plants — across the US have been identified across the USA Other target markets * Mining + Petrochemical * Agriculture + Food & Beverage * Oil & Gas Three channel partner Bi del:
Slide 14: AEC Business Development
AEC Business Development Validates WEVacimcolg AEC
Slide 15: Unsurpassed odor control
UNSURPASSED Cupribyne f ODOR yfriDy, CONTROL Without Fragrances, | Enzymes or Chlorine Compounds | = a L HRB 3 RMT, Oe
Slide 16: Our odor control systems
Our odor control systems + Portable or trailer-mounted systems: + Temp/Litter Fencing + Fans * Batwing + Windrow Turners + Truck Mounted (EcoMist®) + Stationary systems: + Perimeter fence systems + Overhead/Doorway * Bin Washing
Slide 17: Markets
Markets 1. MSW (Municipal Solid Waste) 2. Petrochemical (oil and gas emissions) - Working with Chevron on storage tank decommissioning. WD . Automotive (paint emissions) - New project completed for one of the largest auto manufacturers in the U.S. 4. Wastewater Treatment a . Livestock Rendering 6. F
Slide 18: POOPH - Private label product
POOPH - Private label product Pet stain and odor (testing now for other products) Veteran consumer product experts ~$500K in purchases from ONM ONM receives manufacturer's margin and a royalty on sales ONM receives 20% of the exit Business strategy: ramp up sales and sell to a major consumer product
Slide 19: Flexible, Energy-Efficient Advanced Oxidation for Disinfection and Decontamination
Flexible, Energy-Efficient Advanced Oxidation for Disinfection and Decontamination AOS Why AOS? + Innovative & disruptive technology * Energy efficient + Low cost + Water savings + High performance + Modular, flexible, scalable * Eco-friendly
Slide 20: Montreal Pilot - Disinfection and Pharmaceutical Removal
Montreal Pilot - Disinfection and Pharmaceutical Removal * Better at removing pharmaceuticals than current technologies + Well-suited for municipal and industrial wastewaters + 78-97% removal of examined pharmaceuticals by AOS + Pilot showed AOS operating cost lower than competing technologies in th
Slide 21: Poultry Pilot
Poultry Pilot * Demonstrated performance at pilot scale * Cost effective solution for the poultry processing industry * Strong value proposition proven vv wv Low operating Less pre- 52% cheaper than O, cost confirmed treatment 48% cheaper than Cl, than UV
Slide 22: New Poultry Water Project
New Poultry Water Project $ ene Commercial Trial Potential Revenue: +$1.6 million Multi-unit Treatment Train with AOS Non Potable Reuse Agri-irrigation
Slide 23: What's next for BioLargo Water?
What's next for BioLargo Water? 1. Land first customer for AOS 2. Add AEC to AOS Montreal : —s project = 3. Secure strategic partners and distributors
Slide 24: Clyra Medical: Novel Solution for Infection Control
Novel Solution for Infection C LY R N Control Medical Technologies Inc
Slide 25: We Have a Solution for Chronic Infection
>» We HaveaS for Chronic Inf * Chron infections afect 17 WM people + 550,000 deat + Role of bacteria in producing acute infection more understood * But role of bacteria in clinical differences of chronic infection remains poorly understood + Biofilm is a group of microbial cells that are irreversibl
Slide 26: The Clyra Advantage
THE CLYRADVANTAGE ; Wound and Dental and Orthopedic Burn Oral Surgery iyra™ Antimicrobial Platform Infection Prevention & Control
Slide 27: Bioclynse - Orthopaedic Market Scope
@ cues Bioclynse - Orthopaedic Market Scope + Almost 2,000,000 knee/hip replacements in the U.S. annually * Orthopedic total joint surgeons - 20 procedures per month on average + 2 liters of Bioclynse will typically be used during a procedure at $150/liter representing $6,000/month revenue per surge
Slide 28: Bioclynse - Business Development
. . Ocivrs Bioclynse - Business Development Distribution through market leaders New National Sales Director hired May 1, 2022 Breast implant trial underway New patents issued/notice of allowance received, for orthopedic infection treatment and use against Coronavirus
Slide 29: Contact
OTCOB: BLGO Contact: Dennis Calvert President & CEO BioLargo, Inc. 14921 Chestnut St. Westminster, CA (888) 400-2863 de@BioLargo.com www.BioLargo.com The BioLargo 6 BioLargo Family of Companies feweeess — exif: clean water, clean air, and advanced antimicrobials for healthcare. (stage vier \GpBioLar